Germany supply disruption unresolved
Third-party supplier disruption continues with no clear timeline for resolution; alternative supplier may take 3-4 quarters.
TORRENTPHARMACEUTICALS / bear-case history
Track the concerns that keep returning.
Torrent Pharmaceuticals · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
JB Pharma integration disruption in Q4
Management expects Q4 to be muted due to change of control and process integration, potentially impacting sales.
GLP-1 launch delays in Brazil
Semaglutide launch delayed to next financial year; regulatory approval timeline uncertain despite prioritization.
US growth dependent on launch timing and competition
US revenue growth is contingent on timely new launches and competitive landscape, which are unpredictable.